Please ensure Javascript is enabled for purposes of website accessibility

What's Behind Health Insurance Innovations Rallying 12% Today

By Todd Campbell – May 4, 2017 at 1:12PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The distributor of innovative health insurance products reported solid first-quarter financials this morning.

What happened

After the company reported better-than-expected first-quarter financials, shares of Health Insurance Innovations (BFYT) are jumping 12% at 1 p.m. EDT.

So what

Health Insurance Innovations is enjoying growing demand for its short-term health insurance and hospital indemnity plans.

Gold coins are stacked in front of a computer monitor showing a rising stock price.

IMAGE SOURCE: GETTY IMAGES.

In the first quarter, the company's revenue increased 31.5% year over year, to $55.9 million. Management also reported today that first-quarter earnings per share were $0.36, or $0.06 better than Wall Street watchers' were anticipating.  The bottom line was up a whopping 112% from last year.

Record policies in force of 345,000 (up 34% from one year ago) have management increasing its full-year outlook, too. It now expects that full-year revenue will grow between 15% to 20% from 2016 to between $212 million and $222 million. If all goes as planned, the company expects that will translate into adjusted EPS of $1.40 to $1.50. Previously, guidance was for sales of up to $220 million, and EPS of up to $1.45.

Now what

Health Insurance Innovations shares are flirting with all-time highs, but an argument can be made that they're still worth buying.

HIIQ Chart

HIIQ data by YCharts.

Republicans haven't given up on hopes to reform health insurance, and depending on what shape reform takes, it's conceivable that it will boost demand for short-term insurance solutions. Even if repeal doesn't happen, this success shows the company can grow nicely.

A valuation argument can also be made for buying shares. The company's trading at about 11.5 times next year's estimates, and those estimates could be heading higher following the company's new guidance and strong first-quarter results. 

Todd Campbell has no position in any stocks mentioned. His clients may have positions in the companies mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.